«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《国际骨科学杂志》[ISSN:1673-7083/CN:31-1952/R]

期数:

2018年01期

页码:

45-53

栏目:

综述

出版日期:

2018-01-30

文章信息/Info

Title:

Factors influencing the prognosis of osteosarcoma: a meta-analysis

作者:

王文剑; 于秀淳

250031, 济南军区总医院骨病科

Author(s):

WANG Wenjian;  YU Xiuchun.

Department of Osteopathy, Jinan Military General Hospital,Jinan 250031, China

关键词:

骨肉瘤;  预后;  Meta分析

Keywords:

Osteosarcoma;  Prognosis;  Meta-analysis

分类号:

-

DOI:

10.3969/j.issn.1673-7083.2018.01.012

文献标识码:

A

摘要:

目的 系统评价骨肉瘤患者预后的影响因素。方法 检索PubMed、EMbase、Springer、Science Direct、Wiley InterScience、ProQuest-Health&Medical Complete、EBSCO-MEDLINE、中国知网(CNKI)、中国生物医学文献数据库(CBM)、万方数据库、中文科技期刊数据库、中国期刊全文数据库。搜集骨肉瘤预后影响因素相关的大样本(病例数>100例)病例对照研究,检索时限为1980年1月1日至2017年3月1日。由2位研究者独立筛选文献、提取资料和评价纳入研究的质量,应用Review Manager 5.3软件进行Meta分析。结果 共24项研究符合纳入标准,总样本量11 677例。Meta分析结果显示:男性患者5年无事件生存率(EFS)略低于女性患者[比值比(OR)=0.81,95% CI 0.71～0.93,P=0.002]; 青少年组(≤14岁)5年EFS较成年组略低(OR=0.77,95%CI 0.63～0.95,P=0.01); 规范化疗未常规开展前,手术联合化疗组5年总生存率高于单纯手术组(OR=2.65,95%CI 1.75～4.02,P<0.000 01); 规范化疗开展后,规范化疗组5年EFS高于非规范化疗组(OR=2.47,95%CI 1.64～3.73,P<0.000 01); 保肢手术组5年EFS高于截肢组(OR=1.94,95%CI 1.61～2.35,P<0.000 01); 化疗效果好组(Huvos分级Ⅲ、Ⅳ级)5年EFS高于化疗效果差组(Huvos分级Ⅰ、Ⅱ级)(OR=2.29,95% CI 1.94～2.69,P<0.000 01); 初诊无肿瘤转移组5年总生存率明显高于初诊伴转移组(OR=5.26,95%CI 3.56～7.79,P<0.000 01)。结论 男性骨肉瘤患者较女性预后略差,手术联合规范化疗能明显提高患者5年EFS,保肢手术预后较好,化疗效果差与初诊伴有肿瘤转移则明显影响骨肉瘤患者预后。

Abstract:

Objective To systemically evaluate factors influencing theprognosis of osteosarcoma.Methods Case-control studies(sample size>100)investigating the factors influencing the prognosis of osteosarcoma published from 1st January 1980 to 1st March 2017 were

参考文献/References

[1] Li X, Zhang Y, Wan S, et al. A comparative study between limb-salvage and amputation for treating osteosarcoma[J]. J Bone Oncol, 2016, 5(1): 15-21.
[2] Allison DC, Carney SC, Ahlmann ER, et al. A meta-analysis of osteosarcoma outcomes in the modern medical era[J]. Sarcoma, 2012, 2012: 704-872.
[3] Kager L, Zoubek A, P?tschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols[J]. J Clini Oncol, 2003, 21(10): 2011-2018.
[4] Rothermundt C, Seddon BM, Dileo P, et al. Follow-up practices for high-grade extremity osteosarcoma[J]. BMC Cancer, 2016, 16(1): 301-306.
[5] Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004[J]. Cancer, 2009, 115(7): 1531-1543.
[6] 张清, 徐万鹏, 郭卫, 等. 我国骨肉瘤治疗现状及改进建议--17家骨肿瘤治疗中心1998-2008年资料分析[J]. 中国骨肿瘤骨病, 2009, 8(3): 129-132.
[7] Stang A. Critical evaluation of the Newcastle-Ottawascale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9): 603-605.
[8] 李国辉. 114例骨肉瘤手术治疗分析[J]. 实用癌症杂志, 1989, 4(8): 178-179.
[9] 孙福祥. 168例骨肉瘤临床分析[J]. 现代医药卫生, 2002, 18(1): 45-46.
[10] 谭平先, 雍碧城, 沈靖南, 等. 413例骨肉瘤化疗、手术和预后的10年随访研究[J]. 中国骨科临床与基础研究杂志, 2011, 3(4): 256-262.
[11] 牛晓辉, 蔡槱伯, 张清, 等. ⅡB期肢体骨肉瘤189例综合治疗临床分析[J]. 中华外科杂志, 2005, 43(24): 1576-1579.
[12] Harting MT, Lally KP, Andrassy RJ, et al. Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients[J]. J Cancer Res Clin Oncol, 2010, 136(4): 561-570.
[13] Xing D, Qasem SA, Owusu K, et al. Changing prognostic factors in osteosarcoma: analysis of 381 cases from two institutions[J]. Hum Pathol, 2014, 45(8): 1688-1696.
[14] Hung GY, Yen HJ, Yen CC, et al. Improvement in high-grade osteosarcoma survival: results from 202 patients treated at a single institution in Taiwan. [J]. Medicine(Baltimore), 2016, 95(15): e3420.
[15] Kim MS, Lee SY, Cho WH, et al. Initial tumor size predicts histologic response and survival in localized osteosarcoma patients[J]. J Surg Oncol, 2008, 97(5): 456-461.
[16] Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report[J]. J Clin Oncol, 2000, 18(24): 4016-4027.
[17] Lee JA. Osteosarcoma in korean children and adolescents[J]. Korean J Pediatr, 2015, 58(4): 123-128.
[18] Eleutério SJ, Senerchia AA, Da Costa CM, et al. Osteosarcoma in patients younger than 12 years old without metastases have similar prognosis as adolescent and young adults[J]. Pediatr Blood Cancer, 2015, 62(7): 1209-1213.
[19] Bacci G, Ferrari S, Longhi A, et al. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy[J]. Eur J Cancer, 2001, 37(1): 32-38.
[20] Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin[J]. J Clin Oncol, 1998, 16(2): 658-663.
[21] Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery(neoadjuvant chemotherapy)for osteosarcoma of the extremities.The istituto rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate(high versus moderate doses)and intraarterial cisplatin. [J]. Cancer, 1990, 65(11): 2539-2553.
[22] Bacci G, Longhi A, Bertoni F, et al. Primary high-grade osteosarcoma[J]. J Pediatr Oncol, 2005, 27(3): 129-134.
[23] Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution[J]. Cancer, 2006, 106(5): 1154-1161.
[24] Wang W, Yang J, Wang Y, et al. Survival and prognostic factors in Chinese patients with osteosarcoma: 13-year experience in 365 patients treated at a single institution[J]. Pathol Res Pract, 2017, 213(2): 119-125.
[25] 郭卫, 杨荣利, 汤小东, 等. 成骨肉瘤新辅助化学药物治疗的疗效分析[J]. 中华医学杂志, 2004, 84(14): 1186-1190.
[26] 谭平先, 雍碧城, 王晋, 等. 单中心四肢骨肉瘤311例预后分析[J]. 中华骨科杂志, 2012, 32(11): 1032-1039.
[27] 王剑鸣, 王占文, 刘争民. 骨肉瘤的治疗方法与预后关系(附218例分析)[J]. 伤残医学杂志, 1997, 5(4): 40-41.
[28] 钟景春, 刘洪波, 姜宏, 等. 原发性骨肉瘤161例疗效分析[J]. 实用肿瘤学杂志, 1991, 5(2): 57-58.
[29] 蔡槱伯, 牛晓辉, 张清. 肢体原发成骨肉瘤综合治疗的远期结果[J]. 中华外科杂志, 2000, 38(5): 329-331.
[30] Joo MW, Shin SH, Kang YK, et al. Osteosarcoma in Asian populations over the age of 40 years: a multicenter study[J]. Ann Surg Oncol, 2015, 22(11): 3557-3564.
[31] Mankin HJ, Hornicek FJ, Rosenberg AE, et al. Survival data for 648 patients with osteosarcoma treated at one institution[J]. Clin Orthop Relat Res, 2004, 429: 286-291.
[32] Petrilli AS, Gentil FC, Epelman S, et al. Increased survival, limb preservation, and prognostic factors for osteosarcoma [J]. Cancer, 1991, 68(4): 733-737.
[33] Samardziski M, Zafiroski G, Tolevska C, et al. Limb-sparing in patients with non-metastatic high-grade osteosarcoma[J]. J BUON, 2009, 14(1): 63-69.
[34] 李健, 郭卫, 杨荣利, 等. 影响骨肉瘤预后因素的探讨[J]. 中国骨肿瘤骨病, 2004, 3(6): 374-379.
[35] 韩康, 赵廷宝, 卞娜, 等. 影响骨肉瘤治疗预后效果的临床因素的研究进展[J]. 现代生物医学进展, 2014, 14(29): 5783-5786.
[36] Bramer J, Van Linge JH, Grimer RJ, et al. Prognostic factors in localized extremity osteosarcoma: a systematic review[J]. Eur J Surg Oncol, 2009, 35(10): 1030-1036.
[37] Smeele LE, Kostense PJ, van der Waall, et al. Effect of chemotherapy on survival of craniofacial osteosarcoma:a systematic review of 201 patients[J]. J Clin Oncol, 1997, 15(1): 363-367.

备注/Memo

备注/Memo:

通信作者: 于秀淳 E-mail: 13969132190@163.com

常用功能

更新日期/Last Update: 2018-01-30